NASDAQ:SYBX Synlogic Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synlogic Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.15 -0.03 (-1.38 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$2.11Now: $2.15▼$2.2050-Day Range$2.08MA: $2.25▼$2.5852-Week Range$1.35Now: $2.15▼$3.46Volume99,739 shsAverage Volume340,450 shsMarket Capitalization$73.46 millionP/E RatioN/ADividend YieldN/ABeta2.15 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingSynlogic has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Synlogic has a forecasted upside of 287.6% from its current price of $2.15.Amount of Analyst CoverageSynlogic has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSynlogic has received 293 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynlogic has received 248 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynlogic has received 54.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote “Outperform” if you believe SYBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 17.95% of the stock of Synlogic is held by insiders.Percentage Held by Institutions44.18% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Synlogic are expected to grow in the coming year, from ($1.84) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.67 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYBX Previous Symbol CUSIPN/A CIK1527599 Webwww.synlogictx.com Phone617-401-9975Debt Debt-to-Equity Ratio0.16 Current Ratio20.18 Quick Ratio20.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.22 million Price / Sales33.09 Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book0.44Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-51,370,000.00 Net Margins-2,761.83% Return on Equity-38.34% Return on Assets-31.85%Miscellaneous Employees74 Outstanding Shares34,166,000Market Cap$73.46 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $2.15 -0.03 (-1.38 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SYBX News and Ratings via Email Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Synlogic (NASDAQ:SYBX) Frequently Asked Questions How has Synlogic's stock price been impacted by COVID-19 (Coronavirus)? Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 39.6% and is now trading at $2.15. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Synlogic? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Synlogic. When is Synlogic's next earnings date? Synlogic is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Synlogic. How were Synlogic's earnings last quarter? Synlogic Inc (NASDAQ:SYBX) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.02. The biotechnology company earned $0.45 million during the quarter, compared to the consensus estimate of $0.35 million. Synlogic had a negative net margin of 2,761.83% and a negative return on equity of 38.34%. View Synlogic's earnings history. When did Synlogic's stock split? How did Synlogic's stock split work? Shares of Synlogic reverse split before market open on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split. What price target have analysts set for SYBX? 4 analysts have issued 1 year price objectives for Synlogic's stock. Their forecasts range from $5.00 to $13.00. On average, they expect Synlogic's stock price to reach $8.33 in the next year. This suggests a possible upside of 287.6% from the stock's current price. View analysts' price targets for Synlogic. Are investors shorting Synlogic? Synlogic saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 349,500 shares, an increase of 36.9% from the August 15th total of 255,300 shares. Based on an average trading volume of 274,800 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.7% of the company's shares are sold short. View Synlogic's Short Interest. Who are some of Synlogic's key competitors? Some companies that are related to Synlogic include Xeris Pharmaceuticals (XERS), Affimed (AFMD), Aldeyra Therapeutics (ALDX), Cyclerion Therapeutics (CYCN), Liminal BioSciences (LMNL), Osmotica Pharmaceuticals (OSMT), Neptune Wellness Solutions (NEPT), Selecta Biosciences (SELB), Immunic (IMUX), ProQR Therapeutics (PRQR), Calithera Biosciences (CALA), NextCure (NXTC), Arbutus Biopharma (ABUS), Lannett (LCI) and MediciNova (MNOV). View all competitors. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM) and Novavax (NVAX). Who are Synlogic's key executives? Synlogic's management team includes the following people: Dr. Peter Barrett, Exec. Chairman (Age 66)Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)Prof. Timothy K. Lu, Co-FounderDr. James J. Collins, Co-Founder What is Synlogic's stock symbol? Synlogic trades on the NASDAQ under the ticker symbol "SYBX." Who are Synlogic's major shareholders? Synlogic's stock is owned by a number of retail and institutional investors. Top institutional investors include Bridgeway Capital Management Inc. (0.62%), Bank of New York Mellon Corp (0.25%), Jane Street Group LLC (0.23%), Verition Fund Management LLC (0.22%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea. View institutional ownership trends for Synlogic. Which institutional investors are selling Synlogic stock? SYBX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View insider buying and selling activity for Synlogic. Which institutional investors are buying Synlogic stock? SYBX stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Verition Fund Management LLC, Bridgeway Capital Management Inc., and Goldman Sachs Group Inc.. View insider buying and selling activity for Synlogic. How do I buy shares of Synlogic? Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Synlogic's stock price today? One share of SYBX stock can currently be purchased for approximately $2.15. How big of a company is Synlogic? Synlogic has a market capitalization of $73.46 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe. What is Synlogic's official website? The official website for Synlogic is www.synlogictx.com. How can I contact Synlogic? Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
